PICK1 (protein interacting with C kinase-1) plays a key role in the regulation of intracellular trafficking of AMPA GluA2 subunit
that is linked with synaptic plasticity. PICK1 is a scaffolding protein and binds numerous proteins through its PDZ domain.
Research showed that synaptic plasticity is altered upon disrupting the GluA2-PDZ interactions. Inhibiting PDZ and GluA2
binding lead to beneficial effects in the cure of neurological diseases thus, preventing PDZ-GluA2 binding is thought to novel
therapeutic target in such diseases. To target this, generally, peptides were synthesized and tested. Though small organic
molecules have been targeted to prevent these interactions, the number of such molecules is inadequate. Thus, in this study,
ten molecular libraries containing large numbers of molecules were screened against the PDZ domain using pharmacophore-based virtual screening to find the best hits for the PDZ domain. Molecular docking, molecular dynamic simulation, and ADME analyses revealed that Hit_III (MolPort-005-050-255) shows efficient binding and drug likeness for the PDZ domain. This study suggests that tested hit may
have potency against the PDZ domain and can be considered effective to treat neurological disorders.
Synthesis, molecular docking and molecular dynamic simulation studies of 2-chloro-5-[(4-chlorophenyl)sulfamoyl]-N-(alkyl/aryl)-4-nitrobenzamide derivatives as antidiabetic agents
